Epigenetic Treatment of Colorectal Cancer

Aberrant DNA methylation and epigenetic dysregulation represent common features of colorectal cancer (CRC) and have been associated with tumor progression and therapy resistance. Therefore, we want to investigate whether epigenetic modulation with the DNA methyltransferase 1 (DNMT1) inhibitor 5-Aza-2’-deoxycytidine (DAC) holds potential for treatment and prevention of specific CRC subtypes. Specifically, we focus on Lynch Syndrome (LS)-associated CRC, which has been linked to increased expression of key regulators of DNA methylation, and on microsatellite stable (MSS) BRAF-mutated CRC, which is characterized by aggressive clinical behavior, poor prognosis and limited durable treatment options.

This project aims to evaluate the therapeutic effects of low-dose DAC particularly its ability to reverse tumor-associated epigenetic alterations and induce a durable anti-tumor response. To address these objectives, functional, molecular, transcriptomic and proteomic analyses will be performed in both in vitro and in vivo models. By improving our understanding of DAC-mediated epigenetic reprogramming, this project may contribute to the development of novel treatment and prevention strategies hereditary and clinically aggressive CRC.

Project team